Loading...
Ce produit n'est pas destiné à diagnostiquer, traiter, guérir ou prévenir toute maladie. Ces déclarations n'ont pas été évaluées par la Food and Drug Administration.
Loading...
Ces informations sont fournies à titre éducatif uniquement et ne remplacent pas un avis médical professionnel, un diagnostic ou un traitement. Consultez toujours votre professionnel de santé avant d'utiliser des plantes, surtout si vous êtes enceinte, allaitez, prenez des médicaments ou avez une condition médicale.
Bacillus subtilis natto
Japanese fermented soybean enzyme for fibrinolytic and cardiovascular support.
Nattokinase is a potent fibrinolytic enzyme derived from Bacillus subtilis natto, traditionally used in Japanese fermented soybeans for cardiovascular support. It is primarily utilized for its anti-thrombotic and blood pressure-reducing effects, with key active compounds including nattokinase itself, vitamin K2 (MK-7), and isoflavones.
Nattokinase exerts its fibrinolytic effects by directly degrading fibrin and activating plasminogen to plasmin, thereby enhancing clot dissolution. It also increases tissue plasminogen activator (tPA) levels and reduces plasminogen activator inhibitor-1 (PAI-1), promoting endogenous fibrinolysis. Additionally, it may lower blood pressure through inhibition of angiotensin-converting enzyme (ACE) and reduce platelet aggregation via modulation of thromboxane A2 and prostacyclin pathways.
Japanese fermented soybean enzyme for fibrinolytic and cardiovascular support.
Nattokinase is a potent fibrinolytic enzyme derived from Bacillus subtilis natto, traditionally used in Japanese fermented soybeans for cardiovascular support. It is primarily utilized for its anti-thrombotic and blood pressure-reducing effects, with key active compounds including nattokinase itself, vitamin K2 (MK-7), and isoflavones.
Nattokinase exerts its fibrinolytic effects by directly degrading fibrin and activating plasminogen to plasmin, thereby enhancing clot dissolution. It also increases tissue plasminogen activator (tPA) levels and reduces plasminogen activator inhibitor-1 (PAI-1), promoting endogenous fibrinolysis. Additionally, it may lower blood pressure through inhibition of angiotensin-converting enzyme (ACE) and reduce platelet aggregation via modulation of thromboxane A2 and prostacyclin pathways.